Roche’s decision to drop Herceptin patent in India opens way for genericsBMJ 2013; 347 doi: http://dx.doi.org/10.1136/bmj.f5197 (Published 19 August 2013) Cite this as: BMJ 2013;347:f5197
- Matthew Limb
The Swiss drug producer Roche has confirmed that it will not pursue a patent application in India for its breast cancer drug trastuzumab (which it markets as Herceptin). The decision could pave the way for manufacturers of generic drugs to make copies of the drug in India, although it could be several years before any of these versions reach patients.
Roche said on Friday 16 August that it would not pursue “Indian patent number 205534,” which would have enabled it to extend the patent on trastuzumab in India until 2019. The company said …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial